Drugs / LMN-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05330182 | Aug 2024 → Jun 2027 expected | Clostridium difficile colitis | Lumen Bioscience, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-04-03 | Lumen Bioscience, Inc. | Results Investigational Oral Biologic Achieves 100% C difficile Clinical Cure in Preliminary Cohort lumen.bio ↗
Today, Lumen Bioscience reported that its investigational oral biologic, LMN-201, achieved a 100% clinical cure rate of C difficile infection (CDI) in the sentinel cohort (Part A) of its RePreve clinical trial. |
| 2021-12-24 | Lumen Bioscience, Inc. | Results Antibody synergy By Brian Finrow and Jim Roberts lumen.bio ↗
In the news release we also shared that LMN-201 met its primary endpoint in Cohort 1 of the ongoing Phase 1 pharmacokinetic dosing study. |
| 2021-12-22 | Lumen Bioscience, Inc. | Results Lumen Bioscience Releases Data on Potent, Orally Delivered Biologic Drug Cocktail for Preventing C. difficile Infection lumen.bio ↗
Preclinical data demonstrate LMN-201’s potential for preventing disease in at-risk patients. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-03 | Lumen Bioscience, Inc. | Investigational Oral Biologic Achieves 100% C difficile Clinical Cure in Preliminary Cohort lumen.bio ↗ |
| 2023-10-16 | Lumen Bioscience, Inc. | Lumen Bioscience awarded $16.2 million in DoD funding to advance LMN-201 through late-stage trials lumen.bio ↗ |
| 2021-12-24 | Lumen Bioscience, Inc. | Antibody synergy By Brian Finrow and Jim Roberts lumen.bio ↗ |
| 2021-12-22 | Lumen Bioscience, Inc. | Lumen Bioscience Releases Data on Potent, Orally Delivered Biologic Drug Cocktail for Preventing C. difficile Infection lumen.bio ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMN-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05330182 ↗ |
| Action | Inhibit | “3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile” NCT05330182 ↗ |
| Modality | Other / unclassified | “whole, dried, non-viable biomass of spirulina (Arthrospira platensis)” NCT05330182 ↗ |
| Route | Oral | “orally delivered” NCT05330182 ↗ |